The European market for hospital-acquired disease testing, valued at USD 4.13 billion in 2024, is expected to expand at a Compound Annual Growth Rate (CAGR) of 1.89% from 2025 to 2033, reaching an estimated worth of USD 4.89 billion by 2033. Also termed as nosocomial infections, hospital-acquired diseases are infections that patients contract during their stay in healthcare institutions due to exposure to bacteria, viruses, fungi, and other pathogens.
Annually, approximately 4.5 million patients acquire hospital-acquired-infections (HAIs) in Europe, leading to more than 16 million additional days of hospitalization, substantial morbidity and mortality. These infections translate into significant economic burden costing more than €7 billion each year in the European Union, according to the European Centre for Disease Prevention and Control (ECDC). The most frequent HAIs include urinary tract infections (UTIs), pneumonia, surgical site infections, and bloodstream infections.
Hospitals are increasingly resorting to advanced diagnostic tools such as molecular testing and traditional microbiological techniques for rapid and accurate identification of causative pathogens. Although these testing solutions have been greatly promoted by technological advancements and strict regulatory frameworks, they come with challenges such as high costs, limited awareness, and resource constraints. However, the market also presents opportunities in the arena of point-of-care testing, the integration of artificial intelligence, and emerging markets in Eastern Europe.
Moreover, the rise of multidrug-resistant organisms (MDROs) like methicillin-resistant Staphylococcus aureus (MRSA) exacerbates the demand for enhanced diagnostic tools. The relentless efforts of healthcare systems towards upholding patient safety and infection control have amplified the adoption of hospital-acquired disease testing technologies.
Molecular diagnostic technologies’ advanced tech features catalyze the Europe hospital-acquired disease testing market. However, the high costs linked to these state-of-the-art technologies could act as a deterrent in the market. Additionally, the limited knowledge and skills among healthcare providers concerning these tools pose a significant challenge in the market.
On the bright side, the increasing adoption of point-of-care (POC) testing solutions offers an attractive opportunity in the European hospital-acquired disease testing market. POC testing has seen about a 40% growth in the last five years, primarily for its ability to provide prompt results, enabling quick intervention and treatment. This, coupled with the integration of artificial intelligence and predictive analysis into hospital-acquired disease testing systems, points towards a promising future for the European market.
However, compliance with the strict regulatory frameworks governing diagnostic tools and the challenges faced due to the geographical disparities in healthcare access present considerable obstacles for the market.The testing methods of molecular diagnostics and conventional testing dominate the European hospital-acquired disease testing market and are expected to maintain their dominance due to their precision, speed, cost-effectiveness, and widespread availability.
Urinary tract infections (UTIs) account for the bulk of the activities in the market and are forecasted to continue as such for their high occurrence among hospitalized patients, especially those with catheters or undergoing urological procedures.
Source: https://www.marketdataforecast.com/market-reports/europe-hospital-acquired-disease-testing-market